The FY2024 (Jun) proxy of iBio names 16 peer companies for pay. Among iBio and these peers, CEO pay was the lowest of 5 and total shareholder return was the lowest of 5.
5th highest of 5in iBio and its pay peers, FY2024 (Jun) by CEO pay:
$1.3M$4.9M
5th highest of 5in iBio and its pay peers, FY2024 (Jun) by total shareholder return:
$2$102
Pay peer group, FY2024 (Jun) proxy
| Savara | ||
| Agenus | ||
| CytomX Therapeutics | ||
| Medicinova | ||
| Alanos Therapeutics | Not disclosed | Not disclosed |
| Arcturus Therapeutics Holdings | Not disclosed | Not disclosed |
| CEL-SCI | Not disclosed | Not disclosed |
| Corbus | Not disclosed | Not disclosed |
| Dyadic | Not disclosed | Not disclosed |
| Dynavax | Not disclosed | Not disclosed |
| Karyopharm | Not disclosed | Not disclosed |
| Morphic | Not disclosed | Not disclosed |
| NightHawk Biosciences | Not disclosed | Not disclosed |
| Sorrento Therapeutics | Not disclosed | Not disclosed |
| Sutro Biopharma | Not disclosed | Not disclosed |
| Y -mAbs Therapeutics | Not disclosed | Not disclosed |
16 companies
Changes by year
FY2023 (Jun) proxy
- RemovedArcus Biosciencespay peer groupdue to its similar business focus, size-relevance
- RemovedChemoCentryxpay peer groupdue to its similar business focus, size-relevance
- RemovedNovavaxpay peer groupdue to its similar business focus, size-relevance
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.